Eltrombopag
Spécifications
496775-61-2Numéro CAS
3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acidNom IUPAC
C25H22N4O4Formule chimique
442.5 g/molMasse molaire
Eltrombopag; 496775-61-2; Eltrombopag [INN]; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; SB497115; Eltrombopag-Isomer; 376591-99-0; SB 497115; 1807882-48-9; (E)-Eltrombopag; (ZE)-Eltrombopag; 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; DTXSID5057753; SB-497115; MFCD20926253; CHEMBL461101; S56D65XJ9G; 3'-{2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; C25H22N4O4; 3'-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid; 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid; NCGC00274067-01; UNII-S56D65XJ9G; (E)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; Eltrombopag free base; HSDB 8212; 496775-61-2 (free base); Eltrombopag (Standard); ELTROMBOPAG [MI]; (E/Z)-Eltrombopag 13C; ELTROMBOPAG [VANDF]; ELTROMBOPAG [MART.]; SCHEMBL18910; ELTROMBOPAG [WHO-DD]; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,; 3'-[[1-(3,4-DiMethylphenyl)-1,5-dihydro-3-Methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; MLS006010024; SCHEMBL164270; SCHEMBL211081; SCHEMBL211082; Eltrombopag (SB-497115); ELTROMBOPAG [EMA EPAR]; AMG531; CHEMBL478463; GTPL6961; orb1224942; orb1305316; CHEMBL3186485; DTXCID6031542; Eltrombopag - Bio-X trade mark; SCHEMBL26684256; SCHEMBL29385318; SCHEMBL29386056; SCHEMBL29386140; SCHEMBL29405370; SCHEMBL30966490; CHEBI:85010; EX-A443; XDXWLKQMMKQXPV-QYQHSDTDSA-N; XDXWLKQMMKQXPV-UHFFFAOYSA-N; Eltrombopag (SB-497115-GR); GLXC-90394; HMS3655B14; HMS3743O17; HMS3751E19; HMS5083K21; SYB23031; Eltrombopag (SB-497115-GR)?; Tox21_113965; BDBM50248106; EBC-13607; EBC-13810; HY-15306R; MFCD21090400; s4502; AKOS015920246; AKOS026750537; AKOS030524935; AKOS037515498; CCG-269152; DB06210; EX-7216; FE22658; SB19101; NCGC00274067-02; NCGC00274067-05; NCGC00274067-07; 3'-(2-(2-(3,4-DIMETHYLPHENYL)-5-METHYL-3-OXO-2,3-DIHYDRO-1H-PYRAZOL-4-YL)HYDRAZONO)-2'-OXO-2',3'-DIHYDRO-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID; 3'-{2-[(4Z)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazono]-6-oxo-cyclohexa-1,3-dien-1-yl]benzoic acid; AS-19180; AS-35176; BE164406; HY-15306; SMR004701208; SY108591; CAS-496775-61-2; NS00031938; SB-497 115; SW219608-1; T2562; SB-497115-GR;SB497115; C75316; EN300-260743; AB01274808-01; AB01274808_02; EN300-1709152; Eltrombopag Impurity 46(Mixture Of Z/E-Isomers); EN300-23586760; Q411588; BRD-K40496271-001-02-5; BRD-K40496271-001-03-3; BRD-K40496271-396-01-1; Z2568748600; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-; (Z)-3 inverted exclamation mark -[2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxopyrazol-4(5H)-ylidene]hydrazino]-2 inverted exclamation mark -oxo-2 inverted exclamation mark ,3 inverted exclamation mark -dihydrobiphenyl-3-carboxylic Acid; (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxybiphenyl-3-carboxylic acid; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]diazenyl]-2'-hydroxy-; 3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazineyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)- [1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxyl ic acid; 3'-{(2E)-2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid; 3'-{(2z)-2-(1-[3,4-dimethylphenyl]-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-(3-{2-[(4Z)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid; 3-[(5E)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; 3-[(5Z)-5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]azo]-2-hydroxy-phenyl]benzoic acidSynonymes
Produits contenant Eltrombopag
REVOLADE 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULAREVOLADE 25 MG POLVO PARA SUSPENSION ORALREVOLADE 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULAELTROMBOPAG CIPLA 75 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGELTROMBOPAG CIPLA 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGELTROMBOPAG CIPLA 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGRevolade 25mgRevolade 25mgRevolade 50mgXyvolef 50 mgXyvolef 25 mgElpagoza
Page 1 sur 2
Entreprises vendant Eltrombopag
CT
Công ty TNHH DRP InterViet NamDR
Dr. Reddy's LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.ChinaZC
ZHIWE ChemTech Co.,LtdChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaWH
Wuxi Hexia Chemical CompanyChinaNE
Novartis Europharm LimitedSpainCE
Cipla Europe Nv Sucursal En EspanaSpainCT
Công ty TNHH Novartis Việt NamViet NamPage 1 sur 2